Keywords: Multiple sclerosis, Novaris, Gilenya, Biogen Idec, Tysabri, Avonex, Teva, Copaxone, Decision Resources

Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers

Article | 30 November 2011

Print This

After one year on the market, share of Swiss drug major Novartis’ (NOVN: VX) Gilenya (fingolimod), the only oral ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in